BDX Stock Analysis — Becton Dickinson
Sector: Healthcare
AI Verdict
BDX trades at 10.9x next year's earnings with sky-high growth expectations, so the valuation is cheap for the growth on offer if its entrenched medical device moat delivers, but any stumble could trigger a painful reset.
Competitive Moat
Becton Dickinson manufactures essential medical devices and supplies, including syringes and diagnostic equipment, which are deeply embedded in hospital procurement and regulatory standards. Its moat comes from high switching costs and regulatory barriers, as hospitals and labs rely on its FDA-approved products and established supply chains.
Summary
A massive 256.8% forward EPS growth estimate has BDX trading at just 10.9x next year's earnings, a deep discount to the sector.
Where It Stands
The stock is up 7.91% over the past year, RSI sits at a neutral 53.3, and its 10.9x forward P/E is less than half the healthcare sector median of 22x.
Key Metrics
- RSI: 53.3 — Neutral
- Trailing P/E: 39.1x
- Forward P/E: 10.9x
- PEG Ratio: 0.15
- Earnings Growth: +2.6%
- Revenue Growth: +0.0%
- Market Cap: $42.4B
- Dividend Yield: 0.03%
- 1-Year Return: 7.91%
- 52-Week High: $187.35
- 52-Week Low: $127.59
Analyst Consensus
9 Buy · 12 Hold · 0 Sell (21 analysts)
Bull Case
With forward EPS expected to surge 256.8%, the current 10.9x forward P/E is cheap for the growth you're getting if those earnings materialize.
Bear Case
If the 39.1x trailing P/E reverts toward the sector median due to a miss on those aggressive growth targets, the stock could see a sharp multiple contraction.
Catalyst to Watch
Watch for the next quarterly earnings — confirmation or disappointment on that 256.8% EPS growth expectation will drive the next move.